FAP and prostate carcinoma: Comparison of 177Lu-FAP-2286 to other radiopharmaceuticals previously reported to be effective (i.e., 177Lu-DOTATATE for neuroendocrine tumors (23) and 177Lu-PSMA-617 for prostate cancer (24)) shows comparable absorbed doses for whole body, bone marrow, and kidneys (21,25,26).